Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Willing and able to provide written informed consent
HCV genotype determined by the Central Laboratory
HCV RNA \> LLOQ at screening
Participated and completed a Gilead sponsored HCV treatment study of direct acting antiviral (DAA) containing regimens.
Male and female of childbearing potential must agree to use protocol specified method(s) of contraception
You may not be if
Current or prior history: Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with treatment, assessment or compliance with the protocol; individuals currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded.
Screening ECG with clinically significant abnormalities
Laboratory results outside of acceptable ranges at screening
Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
Clareo Health | Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study
